Loading...
OTCM
BMYMP
Market cap124bUSD
Mar 27, Last price  
1,003.20USD
1D
-1.05%
Jan 2017
0.59%
Name

Bristol-Myers Squibb Co

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
42.26
EPS
—
Div Yield, %
0.26%
Shrs. gr., 5y
3.44%
Rev. gr., 5y
13.06%
Revenues
48.30b
+7.32%
19,207,000,00017,914,000,00019,348,000,00020,597,000,00018,808,000,00019,484,000,00021,244,000,00017,621,000,00016,385,000,00015,879,000,00016,560,000,00019,427,000,00020,776,000,00022,561,000,00026,145,000,00042,518,000,00046,385,000,00046,159,000,00045,006,000,00048,300,000,000
Net income
-8.95b
L
3,000,000,0001,585,000,0002,165,000,0005,247,000,00010,612,000,0003,102,000,0003,709,000,0001,960,000,0002,563,000,0002,004,000,0001,624,000,0004,457,000,0001,007,000,0004,952,000,0003,439,000,000-8,995,000,0006,994,000,0006,327,000,0008,025,000,000-8,948,000,000
CFO
15.19b
+9.60%
1,836,000,0002,083,000,0003,153,000,0003,707,000,0004,065,000,0004,491,000,0004,840,000,0006,941,000,0003,545,000,0003,148,000,0001,832,000,0002,850,000,0005,275,000,0005,940,000,0008,067,000,00014,052,000,00016,207,000,00013,066,000,00013,860,000,00015,190,000,000
Dividend
Nov 05, 20240.5 USD/sh
Earnings
Apr 25, 2025

Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
URL
https://www.bms.com/
IPO date
Jul 05, 1929
Employees
34,300
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
48,300,000
7.32%
45,006,000
-2.50%
46,159,000
-0.49%
Cost of revenue
23,108,000
27,670,000
27,460,000
Unusual Expense (Income)
NOPBT
25,192,000
17,336,000
18,699,000
NOPBT Margin
52.16%
38.52%
40.51%
Operating Taxes
554,000
400,000
1,368,000
Tax Rate
2.20%
2.31%
7.32%
NOPAT
24,638,000
16,936,000
17,331,000
Net income
(8,948,000)
-211.50%
8,025,000
26.84%
6,327,000
-9.54%
Dividends
(4,863,000)
(4,744,000)
(4,634,000)
Dividend yield
4.24%
4.45%
3.00%
Proceeds from repurchase of equity
(5,155,000)
(8,001,000)
BB yield
4.83%
5.18%
Debt
Debt current
2,227,000
3,281,000
4,400,000
Long-term debt
50,524,000
39,875,000
37,714,000
Deferred revenue
300,000
283,000
Other long-term liabilities
3,099,000
4,591,000
5,046,000
Net debt
41,892,000
28,377,000
30,804,000
Cash flow
Cash from operating activities
15,190,000
13,860,000
13,066,000
CAPEX
(1,248,000)
(1,209,000)
(1,118,000)
Cash from investing activities
(21,352,000)
(2,295,000)
(1,062,000)
Cash from financing activities
5,127,000
(9,416,000)
(16,962,000)
FCF
27,147,000
15,148,000
16,442,000
Balance
Cash
10,859,000
12,280,000
9,123,000
Long term investments
2,499,000
2,187,000
Excess cash
8,444,000
12,528,700
9,002,050
Stockholders' equity
14,019,000
27,567,000
24,571,000
Invested Capital
62,243,000
63,040,300
67,219,950
ROIC
39.33%
26.00%
24.73%
ROCE
35.45%
22.84%
23.85%
EV
Common stock shares outstanding
2,027,000
2,078,000
2,146,000
Price
56.56
10.23%
51.31
-28.69%
71.95
15.40%
Market cap
114,647,120
7.53%
106,622,180
-30.95%
154,404,700
10.31%
EV
156,592,120
135,054,180
185,265,700
EBITDA
34,792,000
27,096,000
28,975,000
EV/EBITDA
4.50
4.98
6.39
Interest
1,947,000
1,166,000
1,232,000
Interest/NOPBT
7.73%
6.73%
6.59%